

University of Massachusetts Medical School

eScholarship@UMMS

[Open Access Articles](#)

[Open Access Publications by UMMS Authors](#)

2016-01-01

Therapeutic rAAVrh10 Mediated SOD1 Silencing in Adult SOD1(G93A) Mice and Nonhuman Primates


Florie Borel

University of Massachusetts Medical School

Et al.

Let us know how access to this document benefits you.

Follow this and additional works at: <https://escholarship.umassmed.edu/oapubs>

 Part of the [Genetics and Genomics Commons](#), [Molecular and Cellular Neuroscience Commons](#), [Nervous System Diseases Commons](#), and the [Therapeutics Commons](#)

Repository Citation

Borel F, Gernoux G, Cardozo B, Metterville JP, Toro Cabrera G, Song L, Su Q, Gao GP, Elmallah MK, Brown RH, Mueller C. (2016). Therapeutic rAAVrh10 Mediated SOD1 Silencing in Adult SOD1(G93A) Mice and Nonhuman Primates. Open Access Articles. <https://doi.org/10.1089/hum.2015.122>. Retrieved from <https://escholarship.umassmed.edu/oapubs/2771>

Creative Commons License



This work is licensed under a [Creative Commons Attribution-Noncommercial 4.0 License](https://creativecommons.org/licenses/by-nc/4.0/)

This material is brought to you by eScholarship@UMMS. It has been accepted for inclusion in Open Access Articles by an authorized administrator of eScholarship@UMMS. For more information, please contact Lisa.Palmer@umassmed.edu.

Therapeutic rAAVrh10 Mediated *SOD1* Silencing in Adult *SOD1*^{G93A} Mice and Nonhuman Primates

Florie Borel,¹ Gwladys Gernoux,¹ Brynn Cardozo,¹ Jake P. Metterville,² Gabriela T. Cabrera,^{1,2} Lina Song,¹ Qin Su,³ Guang Ping Gao,^{1,3} Mai K. Elmallah,^{1,4} Robert H. Brown Jr.,^{2,†} and Christian Mueller^{1,4,†,*}

¹Gene Therapy Center, ²Department of Neurology, ³Vector Core, and ⁴Department of Pediatrics, University of Massachusetts Medical School, Worcester, Massachusetts.

[†]These two authors contributed equally to this work.

Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease; survival in ALS is typically 3–5 years. No treatment extends patient survival by more than three months. Approximately 20% of familial ALS and 1–3% of sporadic ALS patients carry a mutation in the gene encoding superoxide dismutase 1 (*SOD1*). In a transgenic ALS mouse model expressing the mutant *SOD1*^{G93A} protein, silencing the *SOD1* gene prolongs survival. One study reports a therapeutic effect of silencing the *SOD1* gene in systemically treated adult ALS mice; this was achieved with a short hairpin RNA, a silencing molecule that has raised multiple safety concerns, and recombinant adeno-associated virus (rAAV) 9. We report here a silencing method based on an artificial microRNA termed miR-*SOD1* systemically delivered using adeno-associated virus rAAVrh10, a serotype with a demonstrated safety profile in CNS clinical trials. Silencing of *SOD1* in adult *SOD1*^{G93A} transgenic mice with this construct profoundly delayed both disease onset and death in the *SOD1*^{G93A} mice, and significantly preserved muscle strength and motor and respiratory functions. We also document that intrathecal delivery of the same rAAVrh10-miR-*SOD1* in nonhuman primates significantly and safely silences *SOD1* in lower motor neurons. This study supports the view that rAAVrh10-miR-*SOD1* merits further development for the treatment of *SOD1*-linked ALS in humans.

INTRODUCTION

AMYOTROPHIC LATERAL SCLEROSIS (ALS) is a devastating, invariably fatal neurological disease caused by degeneration of the motor neuron system leading to often rapidly progressing paralysis. It has an incidence of about 1.5–2.5 cases in 100,000 persons in the general population in the United States^{1,2} and in Europe,³ or up to about 30,000 new cases of ALS per year in those areas. The average life expectancy in ALS ranges from three to five years postdiagnosis. There is no cure for ALS, and the only FDA-approved treatment to date extends survival by only about three months.⁴

Familial ALS, which represents about 10% of all ALS cases, is inherited as a dominant trait, and of these cases approximately 20% arise from mutations in the gene encoding Cu/Zn cytosolic superoxide dis-

mutase 1 (*SOD1*).⁵ An estimated 12–23% of familial ALS and 1–3% of sporadic ALS patients carry a mutation in this gene; 183 mutations in *SOD1* have been identified (ALS online genetics database). The precise mechanisms whereby mutant *SOD1* proteins are neurotoxic are not fully defined. Evidence suggests that mutant *SOD1* acquires toxicity via conformational instability, misfolding, and some degree of aggregation.⁶ In turn, this activates multiple adverse events that include the unfolded protein response,⁷ endoplasmic reticulum (ER) stress,⁸ mitochondrial damage,⁹ heightened cellular excitability,¹⁰ impaired axonal transport,¹¹ and some elements of apoptotic¹² and necrotic¹³ cell death. Some data suggest that the misfolded mutant *SOD1* protein can spread from cell to cell in a prion-like fashion.¹⁴ Mutant *SOD1* can cause toxic misfolding of wild-type *SOD1*.^{12,15}

*Correspondence: Dr. Christian Mueller, 368 Plantation Street, Worcester, MA 01605. E-mail: chris.mueller@umassmed.edu

© Florie Borel, et al., 2016; Published by Mary Ann Liebert, Inc. This Open Access article is distributed under the terms of the Creative Commons Attribution Noncommercial License (<http://creativecommons.org/licenses/by-nc/4.0/>) which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.

Multiple studies have robustly documented that silencing expression of the mutant SOD1 protein prolongs survival of *SOD1*-linked ALS mice. Approaches to silence *SOD1* have included shRNA,¹⁶ transgene-delivered shRNA,¹⁷ antisense oligonucleotides,¹⁸ and virally delivered silencing elements. Initial viral delivery studies achieved successful attenuation of *SOD1* using a lentivirus.^{19,20} More recent studies have employed recombinant adeno-associated virus (rAAV), which is now the viral vector of choice for many gene therapy approaches. A 2013 study showed that silencing *SOD1* in the high-copy transgenic *SOD1*^{G93A} mouse with an rAAV9-shRNA delayed onset and increased survival in mice treated at birth; treatment at later stages also prolonged survival, but without delaying onset.²¹ The same group later demonstrated the efficacy of this approach in rats, showing that silencing *SOD1* in the upper motor neurons also prolonged survival.²² More recently, rAAV6 and rAAV9 vectors expressing an artificial microRNA (miRNA) against *SOD1* were also shown to prolong survival in P2-treated reduced-copy *SOD1*^{G93A} mice,²³ and the survival benefit was 26% with rAAV6 and 14% with rAAV9, a much more modest result than had been obtained in P1-treated animals by Foust et al.²¹ In the rAAV6/rAAV9 study, no increase in survival or delay in onset was shown when the reduced-copy *SOD1*^{G93A} mice were treated as early adults (P35).²³ Finally, an rAAVrh10 vector expressing an artificial miRNA against *SOD1* extended survival of adult *SOD1*^{G93A} mice (with a reduced transgene copy number) by about 11% when delivered intrathecally, but did not delay onset or showed any improvement in motor function.²⁴

The current study was designed to optimize the efficacy of rAAV-mediated RNAi as a treatment for *SOD1*-linked ALS in adult mice with the expectation that this approach would be clinically applicable. An artificial miRNA molecule was selected to induce silencing. Its expression and efficacy in *SOD1* silencing were quantified using two constructs that compared polymerase II (pol II) to polymerase III (pol III) promoters. These constructs are packaged in rAAVrh10, which was selected both because it demonstrated excellent CNS transduction²⁴ and because it has proven to be safe when delivered to the CNS in humans.²⁵ In the present study, we have delivered the therapy to adult ALS mice (P56–68 high-copy *SOD1*^{G93A} mice) and adult nonhuman primates via intrathecal administration, employing a paradigm that may ultimately be useful as a therapy for mutant *SOD1*-mediated ALS in humans. This proof-of-concept study documents that expressing miR-SOD1 from a pol II or a pol III

promoter significantly prolongs survival after delivery in adult mice, and demonstrates feasibility of intrathecal delivery of the same vector in the non-human primate (NHP) *Callithrix jacchus*.

MATERIALS AND METHODS

In vitro validation

Human embryonic kidney cells (HEK293, 1E6) were transfected with 2 μ g plasmid DNA (Jetprime; PolyPlus) and were harvested at 48 hr posttransfection; total RNA was isolated (Trizol; Life Technologies) and *SOD1* transcripts were quantified by RT-qPCR. Experiments were carried in biological triplicates. HEK293 were transfected with 4 μ g plasmid DNA (Lipofectamine 2000; Life Technologies) and were harvested at 72 hr posttransfection; Western blot was performed as described previously.²⁶

Constructs

For the *in vivo* studies, three constructs were used: a control vector expressing GFP only and two vectors expressing miR-SOD1 driven by either a polymerase II (pol II) or a pol III promoter. The control (CB-GFP) construct is composed of the CMV enhancer, chicken beta-actin promoter (CB) containing the Promega intron, green fluorescent protein (*GFP*) gene, BGH poly A termination signal. The CB-miR-SOD1 construct contains the same CB-GFP cassette, with the addition of two copies of the artificial miRNA designed to target human *SOD1* (miR-SOD1) located within the first intron of the *GFP* gene. The U6-miR-SOD1 construct contains a first cassette composed of the CMV enhancer, CB promoter containing the SV40 and not the Promega intron, GFP, SV40 poly A, and a second cassette composed of the U6 promoter upstream of one copy of miR-SOD1. The same constructs/vector batches were used for the murine experiments.

Viral vectors and vector batches validation before NHP study

rAAVrh10 vectors were produced, and vector particles and vector genome copies (gc) were quantified by the University of Massachusetts Medical School Vector Core. Titers were quantified simultaneously for all batches.

Before the NHP experiment, vector batches were tested in *SOD1*^{G93A} mice for *SOD1* silencing. The mice ($n = 3$ per group) received 2E11 gc of vector intravenously through the lateral tail vein, and liver *SOD1* and *Sod1* knockdown were assessed by RT-qPCR at 2 weeks postinjection (Supplementary

Fig. S1; Supplementary Data are available online at www.liebertpub.com/hum).

Animal experiments

All murine experiments were performed at the University of Massachusetts Medical School and were approved by the Institutional Review Board. Male and female adult (P50–68) high-copy *SOD1*^{G93A} mice (B6SJL.SOD1-G93A; Supplementary Table S1) received 200 μ l of vector intravenously through the lateral tail vein for a total dose of 2E12 gc per animal, and were euthanized upon blinded assessment of advanced paralysis by an experienced animal caretaker. Disease onset was defined as peak body weight (as a consequence of weight loss from denervation-induced muscle atrophy), and disease duration as the period between disease onset and euthanasia. For all these parameters, significance was determined with a log-rank (Mantel–Cox) test. Mice from the CB cohort were obtained from the Jackson Laboratory through Prize4Life. Mice from the U6 cohort were bred in-house and transgene copy number was verified by RT-qPCR (Supplementary Table S1) according to the Jackson Laboratory guidelines: mice with a copy number deviating more than 0.5 Ct from the calibrator were excluded, equivalent to a 16.75–33.25 copy number range.

The *C. jacchus* experiment was performed at the Harvard Primate Center and was approved by the Institutional Review Board. Marmosets were pre-screened for neutralizing antibody (NAb) levels against AAVrh.10 by the University of Massachusetts Medical School Vector Core. In addition, all animals were of similar age (less than 4 years old) and body weight (353–476 g). They received 300 μ l of vector intrathecally at lumbar level for a total dose of 6E12 gc/kg body weight. Tail flick reflex was monitored to confirm proper placement of the needle. The animals were euthanized 18–23 days postinjection.

Physiology measurements

Rotarod. Before measurements, mice were trained on an accelerating rod (Med Associates Inc.) until they could remain on the apparatus for 1 min without falling. They were then subjected to rotarod testing on a biweekly basis. The latency to fall from the apparatus was recorded for a duration of 5 min. Three trials were performed for each animal and the longest time taken to fall was recorded.

Grip strength. Two and four limbs' muscle strength was determined by measuring peak force using a digital grip strength meter (Mark-10 force gauge model M4-2) equipped with a hind limb pull bar. Mice were allowed to grip the metal grids,

and gently pulled backward by the tail until they could no longer hold the grids. The grip force was observed over 3 trials and the maximum force was recorded. Ventilation was quantified using whole-body plethysmography in unrestrained, unanesthetized mice as previously described.^{27–29} Briefly, mice were placed inside a 3.5" \times 5.75" Plexiglas chamber, which was calibrated with known airflow and pressure signals before data collection (EMKA Inc.). Data were collected in 10 sec intervals, and the Drorbaugh and Fenn equation³⁰ was used to calculate respiratory volumes, including tidal volume and minute ventilation. The plethysmography is used with IOX2 software (EMKA Inc.). During both a 30 min acclimation period and subsequent 30–60 min baseline period, mice were exposed to normoxic air (21% O₂, 79% N₂). At the conclusion of the baseline period, the mice were exposed to a brief respiratory challenge, which consisted of a 10 min exposure to hypercapnia (7% CO₂, 21% O₂, balance N₂). Experiments were conducted on paired control and treated animals ($n = 7$). For all the physiological parameters, significance was determined with a two-way ANOVA.

Immunostaining of NHP tissue

Agarose-embedded fixed spinal cord tissue was sectioned at 40 μ m and floating sections were immunostained for GFP. Briefly, the endogenous peroxidases were saturated for 15 min in 0.5% H₂O₂, 10% methanol. The tissue was then permeabilized and blocked for 1 hr in 1% Triton X-100 and 10% normal goat serum (ab7481; Abcam). Sections were incubated in a 1:2000 dilution of primary antibody (anti-GFP antibody ab13970; Abcam) for 5 days at 4°C, then in a 1:400 dilution of secondary antibody (Biotinylated Goat Anti-Chicken IgG Antibody, BA-9010; Vector Labs) for 2 hr at room temperature, then in the avidin/biotinylated enzyme complex (Vectastain Elite ABC kit; Vector Labs PK-6105) for 1 hr at room temperature, and finally in the peroxidase substrate (NovaREdd kit Peroxidase Substrate Kit, SK-4800; Vector Labs). Tissue sections were then dehydrated and mounted before imaging on a Leica DM5500B using Leica Application Suite (Leica Microsystems).

Laser-capture microdissection of motor neurons and RNA isolation

Laser-capture microdissection of motor neurons was performed by an experienced technician at the Harvard NeuroDiscovery Center (~2000 cells per section per animal). RNA was subsequently isolated using Ambion RNAqueous-Micro kit (Life Technologies).

RT-qPCR

First-strand cDNA was synthesized with the High Capacity RNA-to-cDNA kit (Life Technologies). Commercial *hsa SOD1* and *hsa HPRT* were used for the *in vitro* validation, and *hsa SOD1* and *mmu Hprt* TaqMan assays were used for the murine experiment. Custom primers and FAM-labeled probes were designed for detection of *C. jacchus SOD1* and *HPRT* mRNA, but not gDNA. A custom small RNA TaqMan assay was designed for detection of mature miR-SOD1, and a commercially available assay was used for detection of snoRNA-135 (primer and probe sequences or commercial references available in Supplementary Table S2). All TaqMan assays and master mixes were ordered from Life Technologies and used according to the manufacturer's recommendations. RT-qPCR data were analyzed with the $\Delta\Delta C_t$ method.³¹

RNA multiplexed branched fluorescent *in situ* hybridization

Frozen spinal cord tissue was cryosectioned at a thickness of 20 μm . Multiplexed branched fluorescent *in situ* hybridization was performed according to the manufacturer's recommendations (ACDbio). Briefly, the sections were fixed for 15 min at 4°C in 10% neutral-buffered formalin and pretreated with a protease-based solution for 30 min at room temperature to increase availability of the target mRNA. DNA probes were hybridized with the target mRNAs (*GFP* in C1, Alexa488; *SOD1* in C2, Atto 550; *ChAT* in C3, Atto 647) for 1 hr at 40°C and bound probe signal was subsequently amplified through branching before imaging on a Leica DM5500B using Leica Application Suite.

Biodistribution in NHP

Genomic DNA (gDNA) was isolated (DNeasy Blood and Tissue kit; Qiagen) from frozen tissue and ddPCR (Biorad) was performed according to the manufacturer's recommendations using 50 ng of DNA as input and TaqMan assays detecting *GFP* and *Cja albumin* (Supplementary Table S2).

Neutralizing antibody response to AAVrh.10

Serum sampled before injection and at weeks 1 and 3, and CSF sampled at week 3 were heat-inactivated for 30 min at 56°C. AAVrh.10-CMV-LacZ (3E8 gc/well) was incubated with 2-fold serial dilutions of the samples for 1 hr at 37°C, 5% CO₂. The mixture was then added to 1E5 Huh7 cells previously infected with an adenovirus (100 vp/well) and incubated for 18–22 hr at 37°C, 5% CO₂. Cells were washed and developed with Galactor-Star kit (Life Technologies). Luminescence was

measured with a luminometer (Synergy HT, Biotek). The NAb titers are expressed as the highest dilution that inhibited β -galactosidase expression by at least 50% compared with a negative mouse serum control (M5905; Sigma-Aldrich).

RESULTS

Design of an artificial miRNA (miR-SOD1) that is highly efficient *in vitro*

The artificial miRNA miR-SOD1 was designed based on the backbone of cellular miR-155 (Fig. 1a). For the *in vitro* validation, plasmid DNA was transfected into HEK293 cells. Substantial reduction in *SOD1* mRNA (Fig. 1b) and protein levels (Fig. 1c) was verified at 48 and 72 hr posttransfection, respectively. Because it targets a conserved sequence in the *SOD1* gene, miR-SOD1 also recognizes the marmoset mRNA sequence (Fig. 1d).

Administration of miR-SOD1 to adult *SOD1*^{G93A} mice significantly delays disease onset and extends survival

To determine if miR-SOD1 is effective *in vivo* after rAAV-mediated delivery, we tested it in *SOD1*^{G93A} mice in experiments that compared the efficacy of pol II (chicken beta actin or CB) and pol III (U6) promoters. With either promoter, intravenous rAAVrh10-mediated delivery through the tail vein of miR-SOD1 to adult (P56–68), pre-onset *SOD1*^{G93A} mice extends survival (Fig. 2). A significant extension in survival (22 days, or 20%, $n = 14$ –22, $p = 0.0485$) is observed (Fig. 2a) in the group treated with the CB-driven construct (130 days), compared with an age-matched, gender-matched control group (108 days). Survival is prolonged to a greater extent by the CB-miR-SOD1 treatment in the subset of females (34 days, or 32%, $n = 8$ –10, $p = 0.0076$; data not shown). A more robust extension of survival (27 days, or 21%, $n = 15$ –17, $p < 0.0001$) is observed (Fig. 2b) in the group treated with the U6-driven construct (158 days) compared with age-matched, gender-matched littermates (131 days). Such extension in survival is similar to that observed in the only study reporting systemic treatment of adult *SOD1*^{G93A} mice, which was 23% using rAAV9-shRNA.²¹ No signs of toxicity were observed in either group, based on daily assessment of discomfort as well as spinal cord *Hprt* levels by RT-qPCR.

For the CB-driven construct, the delay in disease onset of 11 days (12.5%) was not statistically significant (88 days for the control group vs. 99 days with treatment; Fig. 2c). By contrast, the U6-driven construct did achieve a significant 31-day (31%) delay in onset (from 100 to 131 days, $n = 15$ –




Figure 1. Design and *in vitro* validation of miR-SOD1, an artificial miRNA targeting human *SOD1*. **(a)** miR-SOD1 was designed to have perfect complementarity to human *SOD1*, and is based on the backbone of cellular miR-155. **(b)** HEK293 cells were transfected with 2 μ g plasmid DNA. Cells were harvested at 48 hr posttransfection and RNA was isolated. *SOD1* and *HPRT* transcripts were quantified by RT-qPCR. Relative *SOD1* expression was calculated according to the $\Delta\Delta C_t$ method, and three biological replicates were analyzed. Data are presented as average of the replicates \pm SEM. **(c)** HEK293 cells were transfected with 4 μ g plasmid DNA and cells were harvested and lysed at 72 hr posttransfection. Equal amounts of protein were run on an SDS-PAGE and incubated with anti-SOD1 (red) and anti-beta-actin (green) antibodies. **(d)** Alignment showing perfect complementarity between the human (Hsa) and the marmoset (Cja) mRNA sequences at the mature miR-SOD1 site, but only partial complementarity with the endogenous mouse mRNA sequence (Mmu) in particular including two mismatches within the seed sequence at position 4 and 7. miRNA, microRNA; *SOD1*, superoxide dismutase 1.

17, $p < 0.0001$) for the treated group (Fig. 2d). This exceeds all studies reporting treatment of early adult²³ and adult *SOD1*^{G93A} mice,^{21,24} where no delay in disease onset was reported. This delay in onset is documented in mice at 144–145 days of age, which is passed median survival of untreated *SOD1*^{G93A} mice (Supplementary Videos S1 and S2).

Disease duration was extended by treatment with the CB-miR-SOD1 construct from 18 to 35 days (94%, $p = 0.0015$; Fig. 2e). A similar disease duration was observed for the U6-miR-SOD1-treated (34 days) and the untreated (33 days) group (Fig. 2f), indicating that the increased survival observed in this group can be attributed primarily to a delay in onset.

Administration of miR-SOD1 to adult *SOD1*^{G93A} mice significantly preserves limb strength and motor skills, and stabilizes respiratory physiology

A significant preservation in two and four limbs' strength was observed (Fig. 3a and b), in-

dicating that the treatment efficiently delays muscle wasting ($p < 0.0001$ for both parameters). Moreover, the treatment significantly preserved motor skills as assessed by rotarod performance test ($p = 0.0028$), where there is a remarkable difference in latency to fall in mice 120 days of age and older (Fig. 3c).

During the normoxic baseline conditions, the U6-miR-SOD1-treated and the untreated *SOD1*^{G93A} mice showed similar tidal volume, peak inspiratory flow, minute ventilation, and breathing frequency (Fig. 3d–g). However, during a 10 min hypercapnic respiratory challenge, the breathing pattern of the treated *SOD1*^{G93A} mice demonstrated a larger tidal volume and minute ventilation (Fig. 3d; $p = 0.0043$ and Fig. 3f; $p = 0.0137$) as compared with the control group. In addition, treated mice had a more robust peak inspiratory flow indicative of inspiratory muscle strength (Fig. 3e; $p = 0.0455$) as compared with controls. There was no significant difference in frequency between the two groups (Fig. 3g; $p = 0.1208$).




Figure 2. Reducing *SOD1* expression prolongs survival in *SOD1*^{G93A} mice. *SOD1*^{G93A} mice were injected intravenously through the tail vein with 2E12 gc vector and were monitored daily by an experienced, blinded animal caretaker until they were euthanized. The mice were treated with either (a) the CB-driven miR-SOD1 or (b) the U6-driven miR-SOD1. (a) Median survival is 108 days for the control group and 130 days for the CB-miR-SOD1 group, $p=0.0485$. (b) Median survival is 131 days for the control group and 158 days for the U6-miR-SOD1 group, $p<0.0001$. (c) Disease onset is 88 days for the control group and 99 days for the CB-miR-SOD1 group. (d) Disease onset is 100 days for the control group and 131 days for the U6-miR-SOD1 group, $p<0.0001$. (e) Median disease duration was 18 days for the control group and 35 days for the CB-miR-SOD1 group, $p=0.0015$. (f) Median disease duration was 34 days for the control group and 33 days for the U6-miR-SOD1 group. Statistical analysis of the survival, onset, and disease duration data was performed (log-rank test).

Lumbar intrathecal rAAVrh10-mediated delivery of miR-SOD1 silences *SOD1* along the entire spinal cord in *C. jacchus*

The marmoset (*C. jacchus*) is a New World primate that is commonly used in neuroscience research because of its small size, high birth rate, and easy handling³²; other advantages include efforts toward mapping of the marmoset brain,³³ as well as the successful generation of transgenic marmosets.³⁴ Marmosets have been used in studies for Huntington's,³⁵ Parkinson's,^{36,37} and Alzheimer's diseases.^{38,39} We elected to use marmosets for studies of intrathecal delivery of rAAVrh10-miR-SOD1. Nine marmosets of comparable age and

body weight, and prescreened for low levels of NAb against AAVrh.10, received an intrathecal injection at lumbar level of 6E12 gc/kg body weight in 300 μ l total volume of rAAVrh10 encoding one of the three constructs previously described: CB-GFP, CB-miR-SOD1, and U6-miR-SOD1. Tail-flick response was monitored as a sign of proper needle placement, indicative of piercing of the dura and contact with intradural nerve roots. The animals were split into three groups of three, each gender-matched (Supplementary Table S3). They were euthanized at 18–23 days postinjection to avoid possible immune response to the GFP. Tissues from one animal from each group were fixed upon




Figure 3. Reducing *SOD1* expression preserves limb strength and motor skills, preserves motor neurons, and improves respiratory physiology. Limb strength was quantified by grip strength test for two (a) or four limbs (b). Motor skills of *SOD1*^{G93A} mice were assessed by rotarod performance test (c). Respiratory physiology was assessed at baseline (dotted lines) and during hypercapnia (fill lines), including tidal volume (d), peak inspiratory flow (e), minute ventilation (f), and frequency (g).

euthanasia and used for immunostaining; tissues from the other two animals from each group were frozen upon euthanasia and used for all other end points. The females were subsequently excluded from all further analyses, based on absence of tail-flick response upon needle placement questioning the efficacy of the delivery, which was later confirmed by low GFP levels as determined by RT-qPCR to be significantly lower than in the males.

Biodistribution studies demonstrated that, as expected, the highest number of genome copies per diploid genome (*gc/dg*) was found at the site of injection in the lumbar spinal cord, varying from 25.07 to 227.45 *gc/dg* (Supplementary Fig. S2). In the thoracic spinal cord, 16.46–122.93 *gc/dg* were detected, and 0.63–29.19 *gc/dg* in the cervical spinal cord (Supplementary Fig. S2). The second

highest tissue was the liver with a range of 44.42–138.18 *gc/dg* (Supplementary Fig. S2). Vector genomes were also detected in the brain with values ranging from 0.08 to 7.73 *gc/dg*, although a limited number of samples was available for biodistribution (Supplementary Fig. S2).

In addition, CNS transduction was evaluated by immunostaining for GFP. Robust GFP staining was seen at the injection site at LSC level all the way to CSC level (Fig. 4a–c), confirming that this delivery route allows vector delivery to the entire spinal cord. Motor neurons (as distinguished based on morphology) stained positive for GFP at all levels of the spinal cord (Fig. 4d–f). As shown in Fig. 6, GFP expression was detected in motor neurons that were positive for both SOD1 and ChAT as determined by RNA expression.




Figure 4. NHP motor neurons are transduced by rAAVrh10. (a–f) Fixed spinal cord tissue was sectioned at 40 μm and incubated with an anti-GFP antibody. Representative images are presented here, with (d–f) being a higher magnification of (a–c) showing specifically the motor neuron-rich ventral horns. (g–i) Frozen spinal cord tissue was sectioned at 20 μm and motor neurons were laser-captured by an experienced technician. Both motor neurons (i) and non-motor neurons tissue (h) were harvested. NHP, nonhuman primate; rAAV, recombinant adeno-associated virus.

Next, *SOD1* silencing was evaluated in the spinal cord. Motor neurons ($n \approx 2,000$) were isolated from 20 μm sections (Fig. 4g) by laser-capture microdissection (Fig. 4g-i); total RNA was isolated from motor neurons (Fig. 4i) and nonmotor neuron tissue (Fig. 4h). *SOD1* mRNA levels were quantified by RT-qPCR (Fig. 5a-f). In motor neurons (Fig. 5a-c), *SOD1* levels are decreased with the CB-miR-SOD1 by 21% in the lumbar region and 8% in the cervical region (thoracic region data not available). With the U6-miR-SOD1 construct, *SOD1* levels are decreased by 93% in the lumbar, 65% in the thoracic, and 92% in the cervical cord region (Fig. 5a). Similar levels of silencing were observed in the nonmotor neuron tissue (Fig. 5d-f). To con-

firm that the observed reduction in *SOD1* mRNA was miRNA-mediated, mature miR-SOD1 levels were quantified by RT-qPCR (Fig. 5g). Levels in the LSC motor neurons of the U6-miR-SOD1-injected animal were four times higher than in the motor neurons of the CB-miR-SOD1-injected animal. Background levels of mature miR-SOD1 were detected in the CB-GFP animal, possibly attributable to contamination during tissue harvesting (Fig. 5g). The levels of *SOD1* silencing positively correlated with the levels of mature miR-SOD1 expression ($R^2 = 0.99$). This analysis was only done in the LSC as limited material was available. *SOD1* levels were next evaluated in the pons and medulla by RT-qPCR. In total tissue homogenates, *SOD1*




Figure 5. *SOD1* silencing in NHP motor neurons and pons/medulla correlates positively with the levels of mature miR-SOD1. *SOD1* and *HPRT* transcripts were quantified by RT-qPCR in spinal cord motor neuron (a-c), non-motor neuron (d-f), and pons/medulla (g) tissue. Mature miR-SOD1 and snoRNA-135 small RNAs were quantified by RT-qPCR in lumbar spinal cord motor neuron and positively correlated with *SOD1* silencing (h). Spinal cords were sectioned into lumbar (a, d, and h), thoracic (b and e), and cervical (c and f). Relative *SOD1* expression and miR-SOD1 expression were calculated according to the $\Delta\Delta\text{Ct}$ method. control, CB-GFP vector; ND, nondetected.

levels are decreased by 20% with the CB-miR-SOD1 construct, and by 35% with the U6-miR-SOD1 construct (Fig. 5h).

Subsequently, RNA multiplex fluorescent *in situ* hybridization was performed, using a *GFP* probe in C1 to mark transduced cells, and a *SOD1* probe in C2 and a *ChAT* probe in C3 to mark cholinergic neurons, including motor neurons (Fig. 6). Positive *ChAT* staining as well as cell morphology were used here for identification of motor neurons in ventral horns. The CB-GFP animal had low levels of *GFP* and high levels of *SOD1* in motor neurons (Fig. 6a and b). The CB-miR-SOD1 animal presented similar fluorescence (data not shown). Consistent with efficient *SOD1* silencing, the spinal cord sections in the U6-miR-SOD1 animal had high levels of *GFP* and low or background levels of *SOD1* in motor neurons (Fig. 6c and d). The se-

lected images are representative. The marked difference in fluorescence between the treated and nontreated animals is consistent with the RT-qPCR data and confirms that *SOD1* expression was substantially attenuated in the motor neuron population.

Preexisting NAb response to AAV has a critical impact on transduction efficiency after vector injection. Therefore, NHPs were screened for NAb to rAAVrh10 before injection and only NHP presenting NAb titers lower than 1:5 were selected to prevent any rAAV vector neutralization. Serum samples were then collected 1 week and 3 weeks after vector administration. Consistent with results already published after IC or IT rAAV injection,⁴⁰ NAb to injected rAAVrh10 vector were detected in all NHPs (Supplementary Table S4). The NAb titers detected at week 1 ranged from




Figure 6. *SOD1* mRNA is undetectable in GFP-positive, ChAT-positive motor neurons of animal treated with U6-miR-SOD1. Twenty-micrometer sections of frozen spinal cord tissue, from either the control animal (**a** and **b**) or the U6-miR-SOD1 animal (**c** and **d**), were incubated with multiplexed probes detecting *GFP* (green), *SOD1* (yellow), and *ChAT* (red) mRNAs. The nuclei were stained with DAPI (blue). Two representative images from different sections are shown for each animal. The scale bar represents 25 μm .

1:80 to 1:640 and then increased between week 1 and week 3 (range 640–1280). We also measured NAb titers in CSF collected at 3 weeks after AAV administration. In contrast to the results obtained in the serum at the same time point, the titers were significantly lower (range 1:5–1:40) with the exception of NHP No. 18, which had a titer of 1:160.

DISCUSSION

Previous studies have shown that viral vectors permit CNS delivery of constructs that reduce expression of the *SOD1* gene and thereby extend survival of transgenic *SOD1*^{G93A} ALS mice. In particular, this was shown with lentivirus²⁰ and rAAV6 and rAAV9^{21,23} in *SOD1*^{G93A} mice and with rAAV9 in *SOD1*^{G93A} rats.²² In the only study in which adult mice (defined as >50 days) were treated with rAAV expressing an artificial miRNA, the treated animals survived 11% longer, and disease onset was not delayed.²⁴ Here we report extending survival by 20% (22 days) with pol II-miR-SOD1 and 21% (29 days) with pol III-miR-SOD1, and we also report delaying disease onset by 31% (31 days) with the pol III, but not with the pol II. Finally, whereas disease duration is not affected by the U6-miR-SOD1 treatment, the CB-miR-SOD1 significantly slows down disease progression. Although the two studies were done at different times, the experimental protocol was identical, and it is not clear why a change of promoter would lead to such difference, and will be further investigated. The male/female ratio is also different in each study and may account for the difference. The strength of the murine study lies in the robust preservation of two and four limbs' strength, rotarod performance, and ventilation, which support our survival data. Interestingly, although the respiratory phenotype of the *SOD1*^{G93A} mice has been characterized as early as 2006,⁴¹ to our knowledge no therapy has ever reported to slow down or stabilize the respiratory phenotype in these mice. Because the mice recapitulate the respiratory phenotype of ALS patients, these results highlight the potential of the proposed therapy for clinical use.

Another difference in this study is that we used an artificial miRNA to reduce *SOD1* expression, whereas most of the previous studies used shRNA. This allowed us to do a promoter comparison that had never been done in this context. Pol II- and pol III-driven artificial miRNAs present a number of advantages over pol III-driven shRNAs, including improved safety. This is thought to be related to the accuracy of the processing of the miRNA over the shRNA hairpin molecule.⁴² As mentioned pre-

viously, no toxicity was observed in the current study; in addition to the use of an artificial miRNA, this may also reflect the fact that we used lower vector doses than in prior studies reporting toxicity.^{43,44} Nevertheless, the lack of toxicity in this study is noteworthy given that CNS-related toxicity has been reported on various occasions.^{42,45–49} Although in the NHP robust silencing was observed only with the U6-driven construct, optimization of the expression cassette and delivery technique may improve knockdown with the CB-driven construct.

Our study is also distinguished by the use of serotype rh.10 instead of rAAV9 and rAAV6. Although it was shown that rAAV9 transduces motor neurons after systemic injection of a newborn NHP,⁵⁰ intrathecal delivery of rAAV9 in NHPs lead primarily to transduction of astrocytes.⁵¹ The use of rh.10 is a point that may be favorable in this case where motor neurons are the primary target. Indeed, we demonstrate here excellent transduction of motor neurons. From an epidemiological perspective, the use of rh.10 over 9 would not be disadvantageous; the prevalence of NAb is equivalent for both serotypes.⁵² In addition, several clinical trials with rAAVrh10 are currently ongoing (NCT01414985, NCT01801709, NCT01161576, and NCT02168686); this should generate further safety data for this AAV capsid.

In this proof-of-concept, translational study, another critical issue is the method of delivery of the viral vector; this is particularly important in considering the transition from rodents to a large-animal model. We report here that lumbar intrathecal delivery of an rAAVrh10 vector allows excellent transduction of motor neurons all along the entire spinal cord, extending rostrally into the distal brainstem. It is clear that this approach, when coupled with an appropriately active promoter, results in substantial reduction of *SOD1* expression. A major obstacle encountered in this study was the technical challenge of the intrathecal delivery, leading to a high rate of failure (3/9 animals); this was largely a consequence of the relatively small size of the marmosets. Our forthcoming studies will continue to focus on optimizing delivery to the cerebrospinal fluid, examining several variables: (1) using injections into the cisterna magna in addition to the lumbosacral regions; (2) maintaining the subjects in the Tredelenburg position postadministration, a method that improves transduction of the thoracic and cervical segments of the spinal cord⁵³; (3) implanting the catheter into the intrathecal space several days in advance of the infusion, a technique that will allow healing around the catheter

entry zone and thereby reduce backflow leakage during infusion; and (4) using larger NHPs. Although more can be done to refine our delivery system, this study nonetheless demonstrates the considerable potential of using rAAVrh10 for intrathecal delivery of an miRNA to silence expression of the *SOD1* gene as well as the feasibility of moving to animals larger than ALS mice or rats. In our view, this improved intrathecal delivery protocol will allow us to generate robust and reproducible data that will support clinical development of this therapy for *SOD1*-mediated ALS.

ACKNOWLEDGMENTS

We acknowledge Prize4Life for providing some of the mice used in this study. The laser-capture microdissection was done by Charles R. Vanderburg (Harvard NeuroDiscovery Center). We are

grateful to Nicholas Wightman (University of Massachusetts Medical School [UMMS]) for developing the *SOD1* Western blot assay and to Alexandra Weiss (UMMS) for help with the mouse colony. This work was funded by ALS Alliance Therapy (R.H.B.), the Rizzuto fund (R.H.B.), and NINDS NS088689 (C.M. and R.H.B.). R.H.B. also receives support from the NINDS (NS079836), the ALS Association, the Angel Fund, the Al-Athel Foundation, the Pierre L. de Bourgknecht ALS Research Foundation, Project ALS, and P2ALS.

AUTHOR DISCLOSURE

No competing financial interests exist for F.B., G.G., B.C., J.P.M., G.C.T.C., L.S., Q.S., and M.K.E. C.M. and R.H.B. are both inventors on a patent application that covers *SOD1* silencing with the vectors described in this article.

REFERENCES

- McGuire V, Longstreth WT Jr., Koepsell TD, et al. Incidence of amyotrophic lateral sclerosis in three counties in western Washington state. *Neurology* 1996;47:571–573.
- Sorenson EJ, Stalker AP, Kurland LT, et al. Amyotrophic lateral sclerosis in Olmsted County, Minnesota, 1925 to 1998. *Neurology* 2002;59:280–282.
- Logroscino G, Traynor BJ, Hardiman O, et al. Incidence of amyotrophic lateral sclerosis in Europe. *J Neurol Neurosurg Psychiatry* 2010;81:385–390.
- Miller RG, Mitchell JD, Lyon M, et al. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). *Amyotroph Lateral Scler Other Motor Neuron Disord* 2003;4:191–206.
- Rosen DR. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. *Nature* 1993;364:362.
- Prudencio M, Hart PJ, Borchelt DR, et al. Variation in aggregation propensities among ALS-associated variants of *SOD1*: correlation to human disease. *Hum Mol Genet* 2009;18:3217–3226.
- Hetz C, Thielen P, Matus S, et al. XBP-1 deficiency in the nervous system protects against amyotrophic lateral sclerosis by increasing autophagy. *Genes Dev* 2009;23:2294–2306.
- Nishitoh H, Kadowaki H, Nagai A, et al. ALS-linked mutant *SOD1* induces ER stress- and ASK1-dependent motor neuron death by targeting Derlin-1. *Genes Dev* 2008;22:1451–1464.
- Pickles S, Destroismaisons L, Peyrard SL, et al. Mitochondrial damage revealed by immunoselection for ALS-linked misfolded *SOD1*. *Hum Mol Genet* 2013;22:3947–3959.
- van Zundert B, Izaurieta P, Fritz E, et al. Early pathogenesis in the adult-onset neurodegenerative disease amyotrophic lateral sclerosis. *J Cell Biochem* 2012;113:3301–3312.
- Song Y, Nagy M, Ni W, et al. Molecular chaperone Hsp110 rescues a vesicle transport defect produced by an ALS-associated mutant *SOD1* protein in squid axoplasm. *Proc Natl Acad Sci U S A* 2013;110:5428–5433.
- Sundaramoorthy V, Walker AK, Yerbury J, et al. Extracellular wildtype and mutant *SOD1* induces ER-Golgi pathology characteristic of amyotrophic lateral sclerosis in neuronal cells. *Cell Mol Life Sci* 2013;70:4181–4195.
- Re DB, Le Verche V, Yu C, et al. Necroptosis drives motor neuron death in models of both sporadic and familial ALS. *Neuron* 2014;81:1001–1008.
- Munch C, O'Brien J, Bertolotti A. Prion-like propagation of mutant superoxide dismutase-1 misfolding in neuronal cells. *Proc Natl Acad Sci U S A* 2011;108:3548–3553.
- Bosco DA, Morfini G, Karabacak NM, et al. Wild-type and mutant *SOD1* share an aberrant conformation and a common pathogenic pathway in ALS. *Nat Neurosci* 2010;13:1396–1403.
- Maxwell MM, Pasinelli P, Kazantsev AG, et al. RNA interference-mediated silencing of mutant superoxide dismutase rescues cyclosporin A-induced death in cultured neuroblastoma cells. *Proc Natl Acad Sci U S A* 2004;101:3178–3183.
- Xia X, Zhou H, Huang Y, et al. Allele-specific RNAi selectively silences mutant *SOD1* and achieves significant therapeutic benefit *in vivo*. *Neurobiol Disease* 2006;23:578–586.
- Smith RA, Miller TM, Yamanaka K, et al. Antisense oligonucleotide therapy for neurodegenerative disease. *J Clin Invest* 2006;116:2290–2296.
- Ralph GS, Radcliffe PA, Day DM, et al. Silencing mutant *SOD1* using RNAi protects against neurodegeneration and extends survival in an ALS model. *Nat Med* 2005;11:429–433.
- Raoul C, Abbas-Terki T, Bensadoun JC, et al. Lentiviral-mediated silencing of *SOD1* through RNA interference retards disease onset and progression in a mouse model of ALS. *Nat Med* 2005;11:423–428.
- Foust KD, Salazar DL, Likhite S, et al. Therapeutic AAV9-mediated suppression of mutant *SOD1* slows disease progression and extends survival in models of inherited ALS. *Mol Ther* 2013;21:2148–2159.
- Thomsen GM, Gowing G, Latter J, et al. Delayed disease onset and extended survival in the *SOD1*G93A rat model of amyotrophic lateral sclerosis after suppression of mutant *SOD1* in the motor cortex. *J Neurosci* 2014;34:15587–15600.
- Dirren E, Aebischer J, Rochat C, et al. *SOD1* silencing in motoneurons or glia rescues neuromuscular function in ALS mice. *Ann Clin Transl Neurol* 2015;2:167–184.
- Wang H, Yang B, Qiu L, et al. Widespread spinal cord transduction by intrathecal injection of rAAV delivers efficacious RNAi therapy for amyotrophic lateral sclerosis. *Hum Mol Genet* 2014;23:668–681.
- Zerah M, Pigué F, Colle MA, et al. Intracerebral gene therapy using AAVrh.10-hARSA recombinant vector to treat patients with early-onset forms of metachromatic leukodystrophy: preclinical feasibility and safety assessments in nonhuman primates. *Hum Gene Ther Clin Dev* 2015;26:113–124.
- Wright PD, Wightman N, Huang M, et al. A high-throughput screen to identify inhibitors of *SOD1* transcription. *Front Biosci* 2012;4:2801–2808.
- EIMallah MK, Falk DJ, Lane MA, et al. Retrograde gene delivery to hypoglossal motoneurons using

- adeno-associated virus serotype 9. *Hum Gene Ther Methods* 2012;23:148–156.
28. Elmallah MK, Falk DJ, Nayak S, et al. Sustained correction of motoneuron histopathology following intramuscular delivery of AAV in pompe mice. *Mol Ther* 2014;22:702–712.
29. ElMallah MK, Pagliardini S, Turner SM, et al. Stimulation of respiratory motor output and ventilation in a murine model of Pompe disease by ampakines. *Am J Respir Cell Mol Biol* 2015;53:326–335.
30. Drorbaugh JE, Fenn WO. A barometric method for measuring ventilation in newborn infants. *Pediatrics* 1955;16:81–87.
31. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the $2^{-\Delta\Delta C(T)}$ method. *Methods* 2001;25:402–408.
32. Mansfield K. Marmoset models commonly used in biomedical research. *Comp Med* 2003;53:383–392.
33. Okano H, Mitra P. Brain-mapping projects using the common marmoset. *Neurosci Res* 2015;93:3–7.
34. Sasaki E, Suemizu H, Shimada A, et al. Generation of transgenic non-human primates with germline transmission. *Nature* 2009;459:523–527.
35. Kendall AL, Rayment FD, Torres EM, et al. Functional integration of striatal allografts in a primate model of Huntington's disease. *Nat Med* 1998;4:727–729.
36. Ando K, Maeda J, Inaji M, et al. Neurobehavioral protection by single dose l-deprenyl against MPTP-induced parkinsonism in common marmosets. *Psychopharmacology* 2008;195:509–516.
37. Gnanalingham KK, Smith LA, Hunter AJ, et al. Alterations in striatal and extrastriatal D-1 and D-2 dopamine receptors in the MPTP-treated common marmoset: an autoradiographic study. *Synapse* 1993;14:184–194.
38. Baker HF, Ridley RM, Duchen LW, et al. Experimental induction of beta-amyloid plaques and cerebral angiopathy in primates. *Ann N Y Acad Sci* 1993;695:228–231.
39. Maclean CJ, Baker HF, Ridley RM, et al. Naturally occurring and experimentally induced beta-amyloid deposits in the brains of marmosets (*Callithrix jacchus*). *J Neural Transm* 2000;107:799–814.
40. Gray SJ, Nagabhushan Kalburgi S, McCown TJ, et al. Global CNS gene delivery and evasion of anti-AAV-neutralizing antibodies by intrathecal AAV administration in non-human primates. *Gene Ther* 2013;20:450–459.
41. Tankersley CG, Haeggeli C, Rothstein JD. Respiratory impairment in a mouse model of amyotrophic lateral sclerosis. *J Appl Physiol* 2007;102:926–932.
42. McBride JL, Boudreau RL, Harper SQ, et al. Artificial miRNAs mitigate shRNA-mediated toxicity in the brain: implications for the therapeutic development of RNAi. *Proc Natl Acad Sci U S A* 2008;105:5868–5873.
43. Borel F, van LR, Koornneef A, et al. *In vivo* knock-down of multidrug resistance transporters ABCC1 and ABCC2 by AAV-delivered shRNAs and by artificial miRNAs. *J RNAiGene Silencing* 2011;7:434–442.
44. Grimm D, Streetz KL, Jopling CL, et al. Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways. *Nature* 2006;441:537–541.
45. Boudreau RL, Martins I, Davidson BL. Artificial microRNAs as siRNA shuttles: improved safety as compared to shRNAs *in vitro* and *in vivo*. *Mol Ther* 2009;17:169–175.
46. Ehlert EM, Eggers R, Niclou SP, et al. Cellular toxicity following application of adeno-associated viral vector-mediated RNA interference in the nervous system. *BMC Neurosci* 2010;11:20.
47. Khodr CE, Sapru MK, Pedapati J, et al. An alpha-synuclein AAV gene silencing vector ameliorates a behavioral deficit in a rat model of Parkinson's disease, but displays toxicity in dopamine neurons. *Brain Res* 2011;1395:94–107.
48. Martin JN, Wolken N, Brown T, et al. Lethal toxicity caused by expression of shRNA in the mouse striatum: implications for therapeutic design. *Gene Ther* 2011;18:666–673.
49. Ulusoy A, Sahin G, Bjorklund T, et al. Dose optimization for long-term rAAV-mediated RNA interference in the nigrostriatal projection neurons. *Mol Ther* 2009;17:1574–1584.
50. Foust KD, Wang X, McGovern VL, et al. Rescue of the spinal muscular atrophy phenotype in a mouse model by early postnatal delivery of SMN. *Nat Biotechnol* 2010;28:271–274.
51. Samaranch L, Salegio EA, San Sebastian W, et al. Adeno-associated virus serotype 9 transduction in the central nervous system of non-human primates. *Hum Gene Ther* 2012;23:382–389.
52. Thwaite R, Pages G, Chillon M, et al. AAVrh.10 immunogenicity in mice and humans. Relevance of antibody cross-reactivity in human gene therapy. *Gene Ther* 2015;22:196–201.
53. Meyer K, Ferraiuolo L, Schmelzer L, et al. Improving single injection CSF delivery of AAV9-mediated gene therapy for SMA: a dose-response study in mice and nonhuman primates. *Mol Ther* 2015;23:477–487.

Received for publication September 4, 2015;
accepted after revision December 1, 2015.

Published online: December 28, 2015.